News | Proton Therapy | March 13, 2019

What to Expect from the Proton Therapy Market in 2019-2020

Sales decline continued in 2018, but interest remains high despite financial barriers

What to Expect from the Proton Therapy Market in 2019-2020

March 13, 2019 — The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new report from MEDraysintell, continuing a trend dating back to mid-2016. The report says this trend may change if particle therapy vendors are able to build a strong order book in 2019 and 2020.

Following the large number of new orders for proton therapy equipment reported worldwide during the year 2015, MEDraysintell considered that it was facing a market with strong potential. This positive trend continued until mid-2016, when it began to slow down with a persistent decline in 2017, further confirmed in 2018 as well. Overall, 2018 sales dropped by 62 percent compared to 2015. This decline impacts directly the particle therapy market size (in value by U.S. dollars) evolution, with an anticipated market slowdown of some 25 percent in 2020 compared to 2018. The year 2018 also clearly confirmed the trend in favor of single-room facilities, with 100 percent of the proton therapy orders worldwide oriented towards single-room facilities (compared to less than 40 percent in 2016).

However, a retrospective analysis shows that 2015 was an exceptional year with a record level of orders, and not the new standard expected by the industry, according to the MEDraysintell report. In general, negative publicity, resistance from health authorities and private insurances to reimburse proton therapy, and cost hurdles as a whole have certainly been important factors in the slow adoption of proton therapy facilities in the recent past, the report said. This limited support from investors and healthcare payers remains unchanged and linked to both the higher price of this modality compared to external radiotherapy and the lack of definitive clinical demonstration of superiority (which is under progress).

As of February 2019, there were fewer than 240 particle therapy (mostly proton therapy) treatment rooms available to patients worldwide. This low number represents only 0.3 particle therapy treatment rooms per 10 million people compared to roughly an equivalent 20 radiotherapy systems in the world.

In order to sustain the market growth and to increase the use of proton therapy as an efficient cancer treatment, the PT industry should encourage the research, collection and ongoing publication of clinical evidence, according to MEDraysintell. In addition, stronger marketing is needed in order to grow the referencing of patients toward proton therapy centers. Some mixed signals from the proton therapy area have already been observed — for instance a growing interest of the medical-scientific community stating that at least 10 percent of the population requiring external radiotherapy treatment could benefit from proton therapy. However, this level reached only 0.7 percent in 2018 and almost all operational particle therapy centers are far from saturation levels, with only 17 percent of them able to treat on average over 200 patients per treatment room.

For more information: www.medraysintell.com

Related Proton Therapy Content

VIDEO: Economics of Proton Therapy

VIDEO: The Role of the Physicist in Proton Therapy

360 View of the Gantry Room at the Northwestern Medicine Chicago Proton Center

360 View of the Inclined Beam Room at the Northwestern Medicine Chicago Proton Center

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin